Ischemic Heart Disease Risk Management in Women: Recent Evidence

Presented By:		C. Noel Bairey Merz, MD, FACC Professor of Medicine Director, Women’s Heart Center Director, Preventive and Rehabilitative Cardiac Center Women’s Guild Endowed Chair in Women’s Health Cedars-Sinai Medical Center Los Angeles, California

Program Description:	This CME activity consists of an educational component (ie, slides, audio lecture, newsletter) in an electronic format, followed by an online post-test. Estimated time to complete this activity, including review of materials, is 30 minutes.
General Information:	Requirements for Successful Completion: This CME activity consists of an educational component (ie, slides, audio lecture, newsletter) in an electronic format, which is followed by an online post-test. There is no fee to participate in this CME activity or to receive CME credit. Certificates are awarded upon successful completion (80% proficiency) of the post-test. In order to receive credit, participants must view the presentaion in its entirety. Media: Internet Release Date:    October 24, 2007 Expiration Date:  October 24, 2009
Target Audience:	This CME activity is designed to meet the educational needs of clinical cardiologists, internists, and other healthcare professionals who manage patients with chronic stable angina.
Program Overview:	Ischemic heart disease (IHD) in women can be challenging to diagnose and manage because of gender differences in clinical presentation, disease pathophysiology, and clinical outcomes compared with those in men. Women with IHD are often older and have a greater risk factor burden and more functional disability than men. Although stable angina is typically the initial clinical symptom, women are less likely than men to have test-positive angina and angiographic evidence of obstructive coronary disease. Nevertheless, angina in women with normal coronary arteries is not benign. Women with stable angina have similar cardiovascular mortality to that in men, and women with test-positive angina have a worse prognosis, particularly those in younger age groups. The vascular pathology of IHD in women more often involves increases in endothelial dysfunction and microvascular disease with less evidence of macrovascular disease than in men. Assessments of coronary reactivity, perfusion abnormalities, or plaque burden may be more appropriate than traditional testing to improve detection and management of IHD in women at an early stage. This CME activity is designed to provide physicians with the latest knowledge of gender-based differences in IHD and to outline optimal strategies for better detection, assessment, and treatment aimed at improving outcomes in this population.
Learning Objectives:	• Understand gender differences in IHD presentation, risk factor burden, and morbidity and mortality risk, and translate this information into new approaches to better diagnosis and management in women who present with IHD • Realize that women with IHD are often older and have a greater risk factor burden and more functional disability compared with men, and apply this knowledge to earlier identification of women at high risk • Recognize that younger women with stable angina are at particularly high risk for cardiovascular mortality, and integrate this knowledge into aggressive risk factor management • Appreciate that women with acute myocardial infarction have higher mortality than men, and implement more intensive acute management in women with acute coronary events
Faculty Disclosure:	The University of Florida College of Medicine has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they simply are noted here to fully inform participants. C. Noel Bairey Merz, MD, has indicated that she has a financial arrangement or affiliation with Access Comm Inc, Adventis Health, AstraZeneca, ATS Medical Inc, Bayer AG, Boston Scientific Corporation, Eli Lilly and Company, Hospicom, Johnson & Johnson, Kos Pharmaceuticals Inc, Medtronic Inc, Teva Pharmaceutical Industries Ltd,and Thornton. The types of affiliation/financial interest are consultant agreements, honoraria, and stock holdings.
Continuing Medical Education Credit:
	Accreditation
	The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
	Credit
	The University of Florida College of Medicine designates this educational activity for a maximum of .50 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
	This continuing education activity was planned in accordance with the ACCME essentials and reviewed by Carl J. Pepine, MD, Program Chair.
	Click here for disclosure and disclaimer information
Commercial Support:	This CME activity is supported by an educational grant from CV Therapeutics Inc.
System Requirements:	In order to view the presentation, your computer must have a media player such as Windows Media Player, Quicktime, or RealOne.
CME Contact:	For any question regarding this Internet CME activity, please contact the Office of Continuing Medical Education at 352-265-8081.
	The University of Florida College of Medicine has received permission to use this copyrighted material within a CME activity on the internet.

Take this presentation with you:
Download this Online Lecture as an MP3 and load it onto your iPod or other portable audio player.
MP3 Audio File
(Right-click and select "Save Target As..." to download)